Clinical trials: Adolescent Depression
- Condition Adolescent Depression
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Depressive Disorder
A Study of Duloxetine (LY248686) in Japanese Children and Adolescents With Depressive Disorder
The purpose of this study is to determine the efficacy of duloxetine hydrochloride versus placebo in the treatment of Japanese children and adolescents with depressive disorder.
- Trial name
- NCT03315793
- Testing
- Duloxetine Hydrochloride
- Where
- Japan
- Volunteers
- 149 people
- Sponsor
- Shionogi
Major Depressive Disorder
A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD
This is a 6-month, open-label, flexible-dose study evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in the Treatment of Child and Adolescent Outpatients with Major Depressive Disorder (MDD).
- Trial name
- NCT01371708
- Testing
- DVS SR
- Where
- 36 sites in United States, Chile
- Volunteers
- 283 people
- Sponsor
- Pfizer
Major Depressive Disorder
Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression
The primary purpose of your participation in this study is to help answer the following research question: Whether 12-week administration of EMSAM (selegiline transdermal system) is safe and effective for the treatment of…
- Trial name
- NCT00531947
- Testing
- Selegiline Transdermal System
- Where
- 20 sites in United States
- Volunteers
- 308 people
- Sponsor
- Somerset Pharmaceuticals
Treatment Resistant Depression
Linear Asymmetric rTMS in Adolescent Treatment-Resistant Depression: Treatment Durations From Ten Days to One Day
This is a pilot interventional study to investigate the acceptability, tolerability, and side effect profile for varying numbers of treatment sessions/day of a new rTMS treatment in adolescents with treatment-resistant depression…
- Trial name
- NCT03986658
- Testing
- Linear Asymmetric rTMS System
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- NeuroQore Inc.
Depressive Disorder, Major
Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age
Evaluation of the long-term safety and tolerability of vortioxetine in child and adolescent participants with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5™) diagnosis of MDD.
- Trial name
- NCT02871297
- Testing
- Vortioxetine
- Where
- 78 sites in United States, Bulgaria and 18 more
- Volunteers
- 662 people
- Sponsor
- H. Lundbeck A/S
Suicide, Mental Health Disorder
Optimizing a Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents
Despite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death amongst youth. Digital tools, especially personal smartphones, are promising avenues to address these issues and can be…
- Conditions
- Suicide, Mental Health Disorder, Anhedonia
- Trial name
- NCT06665620
- Testing
- ViraBrite nudges
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ksana Health
Major Depressive Disorder
Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in adolescent outpatients (12-17) with major depressive disorder.
- Trial name
- VLZ-MD-21 (NCT01878292)
- Testing
- Vilazodone
- Where
- 52 sites in United States
- Volunteers
- 529 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder
Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety
- Trial name
- NCT02129751
- Testing
- bupropion hydrobromide
- Volunteers
- 246 people
- Sponsor
- Bausch Health Americas, Inc.
Major Depressive Disorder
Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)
The primary purpose of this study is to evaluate the pharmacokinetics and safety of Zuranolone in adolescents (ages 12 to 17 years) with MDD.
- Trial name
- NCT05655507
- Testing
- Zuranolone
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Biogen
Major Depressive Disorder
A Study in the Treatment of Children and Adolescents With Major Depressive Disorder
The purpose of this study is to assess whether duloxetine is superior to placebo in the treatment of children and adolescents with major depressive disorder (MDD)
- Trial name
- NCT00849693
- Testing
- fluoxetine, duloxetine
- Where
- 56 sites in United States, Argentina and 2 more
- Volunteers
- 463 people
- Sponsor
- Eli Lilly and Company
Depression
Hypericum vs Fluoxetine for Mild to Moderate Adolescent Depression
The study is a pilot study where adolescents 12 - 18 years of age with mild to moderate depression will be randomized to receive either hypericum 250mg twice daily or fluoxetine 10mg daily increased to 20mg daily after 1 week and…
- Trial name
- NCT00557427
- Testing
- hypericum, fluoxetine
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Rafa Laboratories
Screen Time
Characterization of Smartphone-related Diseases Using the Phonix Care Application
The goal of this observational study is to describe how adolescents and young adults use screens in their daily lives and to identify different profiles of screen use ranging from low to excessive.
- Trial name
- PHX_2022_1 (NCT07293208)
- Testing
- PhonixDiag Smartphone Monitoring Tool
- Where
- France
- Volunteers
- 171 people, healthy volunteers welcome
- Sponsor
- Phonix Health
Major Depressive Disorder
Fluvoxamine Maleate in the Treatment of Depression/Depressive State : A Post-marketing Clinical Study in Children and Adolescents
This study is to verify the efficacy of fluvoxamine maleate given for 8 weeks in the treatment of children and adolescents with depression or depressive state
- Trial name
- NCT00353028
- Testing
- Fluvoxamine maleate
- Where
- 25 sites in Japan
- Volunteers
- 90 people
- Sponsor
- Solvay Pharmaceuticals
Major Depressive Disorder
Study of Technology-assisted Treatment of Adolescent Depression
The purpose of this study is to evaluate a computer-guided, telephone-based therapy for adolescent depression, delivered in a pediatric primary setting in the community.
- Trial name
- iTAD (NCT01582581)
- Testing
- Telephonic CBT, Wait List Control
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- iHope Network, Inc.
Major Depressive Disorder
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
This is a 6-month, open-label, flexible-dose study evaluating desvenlafaxine succinate sustained release (DVS SR) in the treatment of child and adolescent outpatients with major depressive disorder (MDD).
- Trial name
- NCT01371721
- Testing
- DVS SR
- Where
- 35 sites in United States, Mexico
- Volunteers
- 269 people
- Sponsor
- Pfizer
Anxiety, Depression in Adolescence
Co-designing Adaptations of a Digital Mental Health Intervention (Wysa) for Adolescent Girls With Anxiety or Depression in Rural India
The goal of this study is to culturally and contextually adapt Wysa, an evidence-based AI-powered digital mental health intervention (DMHI), for adolescent girls (ages 13-18) with symptoms of anxiety and/or depression in rural…
- Conditions
- Anxiety, Depression in Adolescence, Anxiety Disorder of Adolescence
- Trial name
- NCT07595029
- Testing
- Digital psychosocial tool
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Wysa
Major Depressive Disorder
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
This is a Double-blind Study Evaluating Desvenlafaxine Succinate (DVS SR) Sustained Release vs Placebo in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (MDD).
- Trial name
- NCT01372150
- Testing
- desvenlafaxine succinate sustained release, fluoxetine
- Where
- 43 sites in United States, Mexico
- Volunteers
- 340 people
- Sponsor
- Pfizer
Depressive Disorder, Major Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder
The primary purpose of this study is to evaluate the long-term safety and tolerability of Desvenlafaxine Succinate Sustained-Release (DVS SR) in child and adolescent outpatients with major depressive disorder.
- Trial name
- NCT00669110
- Testing
- Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Depression in Adolescence, Anxiety
Application for Arts-Based Social Prescribing
The goal of this clinical trial is to learn if a personalized arts-based social prescribing program, Art Pharmacy, delivered through a mobile app (SocialRx App) can improve mental health and social connectedness in adolescents…
- Conditions
- Depression in Adolescence, Anxiety, Loneliness, Social Connectedness
- Trial name
- NCT07593443
- Testing
- Art Pharmacy, Stable treatment
- Volunteers
- 230 people
- Sponsor
- SocialRx Inc
Depression
A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19
Over 3 million teenagers in the USA have depression, and rates of depression and suicide are sharply increasing. Teenage depression has far-reaching consequences including impairments in academic and work performance and social…
- Trial name
- NCT04524598
- Testing
- Limbix Spark, Psychoeducation
- Where
- United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- Limbix Health, Inc.